Kodu・Aktsiate loetelu・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Suletud

3.53 -14.53

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.5

Max

4.13

Põhinäitajad
By Trading Economics
Sissetulek	-42M -78M
Aktsiakasum	-0.59
Töötajad	106
EBITDA	-42M -77M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+112.77% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	6. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-34M 297M
Eelmine avamishind	18.06
Eelmine sulgemishind	3.53

Zentalis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. aug 2026, 23:56 UTC

Columbia Banking System Inc shares are higher in after-market trading, maintaining an upward trend since Friday's close, with no specific news identified for the movement.

14. aug 2026, 23:56 UTC

Lowe's Companies Inc saw modest gains during after-market hours, trading near the upper end of its one-month range and above its 20-day moving average.

14. aug 2026, 23:56 UTC

CEVA Inc shares are higher in after-market trading, reaching a session high earlier. The stock remains within its one-month trading range.

14. aug 2026, 23:56 UTC

Whirlpool Corp shares are trading lower in after-market hours. No specific news was identified to explain the movement.

14. aug 2026, 23:56 UTC

ETF Constituents

Vanguard FTSE Developed Markets ETF rises in after-market trading, supported by strong performances from top holdings including UL, KB, SAP, FLUT, and CVE.

14. aug 2026, 23:56 UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

14. aug 2026, 23:56 UTC

Aptiv PLC shares are trading higher in after-market hours following an early spike, amid a market characterized by complacency and stable equities.

14. aug 2026, 23:56 UTC

Fox Corp shares are lower in after-market hours, showing unusual volatility. No specific news was identified to explain the movement.

14. aug 2026, 23:56 UTC

Encore Capital Group Inc shares are higher in after-market trading, continuing a positive trend following four consecutive sessions of gains. No specific news was identified.

14. aug 2026, 23:56 UTC

Commercial Metals Co. shares declined after-market, continuing a trend of three consecutive lower daily closes, despite remaining above the 20-day moving average.

14. aug 2026, 23:56 UTC

ETF Constituents

The Consumer Staples Select Sector SPDR Fund is trading higher in after-market hours, supported by gains from top holdings like Monster Beverage and Walmart.

14. aug 2026, 23:56 UTC

Macro News

ETF Constituents

VanEck Gold Miners ETF rises in after-market trading amid U.S.-Iran tensions and a weaker U.S. Dollar Index, boosting demand for safe-haven assets.

14. aug 2026, 23:56 UTC

Cognizant Technology Solutions shares are higher in after-market trading, recovering from earlier losses amid a mixed backdrop in global equity markets.

14. aug 2026, 23:52 UTC

News

Boeing Co secures over $711 million in U.S. defense contract modifications, boosting investor sentiment. Shares are higher in after-market trading.

14. aug 2026, 23:51 UTC

Insight Enterprises Inc. shares are trading slightly lower after-market, amid broader market concerns following a surprising decline in U.S. retail sales for July.

14. aug 2026, 23:51 UTC

Turning Point Brands Inc shares are higher in after-market hours, trading above their 20-day moving average amid broader market concerns over declining U.S. retail sales.

14. aug 2026, 23:51 UTC

ETF Constituents

Energy Select Sector SPDR Fund rose in after-market hours, driven by gains from Valero Energy, Chevron, and Exxon Mobil, offsetting minor declines from Marathon and Occidental.

14. aug 2026, 23:51 UTC

Vipshop Holdings Ltd shares are higher in after-market hours, diverging from recent declines despite a drop in U.S. retail sales for July.

14. aug 2026, 23:51 UTC

Kanzhun Ltd. shares are lower in after-market hours, reflecting a decline following disappointing U.S. retail sales data and shifting market sentiment on interest rates.

14. aug 2026, 23:51 UTC

Cognex Corp shares are lower in after-market hours amid broader market concerns following a decline in U.S. retail sales for July.

14. aug 2026, 23:51 UTC

Abercrombie & Fitch Co shares are lower in after-market hours following a decline in U.S. retail sales for July, raising concerns about consumer spending.

14. aug 2026, 23:51 UTC

RingCentral Inc. shares are higher in after-market trading, reflecting positive momentum following Friday's close, despite concerns over July's U.S. retail sales decline.

14. aug 2026, 23:51 UTC

Social Media

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

14. aug 2026, 23:51 UTC

Tower Semiconductor shares are higher in after-market trading, remaining above their 20-day moving average despite a decline in U.S. retail sales for July.

14. aug 2026, 23:51 UTC

Karyopharm Therapeutics shares are higher in after-market trading, despite no specific news. Broader market sentiment reflects concerns from a decline in U.S. retail sales.

14. aug 2026, 23:51 UTC

News

PayPal is in advanced talks for a potential sale to Stripe and Advent, following a proposal of $60.50 per share. Shares are higher in after-market trading.

14. aug 2026, 23:51 UTC

China's House Price Index YoY release on August 17, 2026, signals cautious market sentiment amid ongoing housing challenges and weak demand.

14. aug 2026, 23:51 UTC

Social Media

BJ's Wholesale Club Holdings Inc. is trading higher in after-market hours following its scheduled earnings report amid positive market sentiment despite a drop in U.S. retail sales.

14. aug 2026, 23:51 UTC

Griffon Corp shares are lower in after-market hours amid weak market sentiment and disappointing U.S. retail sales data, which diverged from expectations.

14. aug 2026, 23:51 UTC

In after-market trading, Bloomin' Brands Inc is moving higher, reflecting strong performance despite a decline in U.S. retail sales for July.

Võrdlus sarnastega

Hinnamuutus

Zentalis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

112.77% tõus

12 kuu keskmine prognoos

Keskmine 8.83 USD 112.77%

Kõrge 11 USD

Madal 5 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Zentalis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Zentalis Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.